Abstract
Purpose
Hyperthermic intraperitoneal chemotherapy (HIPEC) potentially confers significant survival benefits in the management of ovarian cancer although the long-term data remain scant. We sought to compare the survival rates of advanced stage ovarian cancer patients who were treated with primary induction therapy alone or in conjunction with consolidation HIPEC.
Methods
69 ovarian cancer patients who underwent surgery and completed their primary induction chemotherapy were treated with consolidation carboplatin (AUC 10) based HIPEC and compared to a historical cohort that received surgery and primary chemotherapy alone (n = 69). The demographic and clinical characteristics on which we were primarily focused, included patient age, body mass index, surgery and pathology data, chemotherapy regimen, toxicity, and progression free/overall survival.
Results
The two patient groups’ demographic and clinical characteristics were similar (P > 0.05). Progression-free survival was significantly more pronounced in the HIPEC (25.1 months) patients compared to the control group (20 months) (P = 0.024) and there was a decreased risk of disease progression accorded to the patients treated with HIPEC (HR 2.1028; 95% CI 1.2941–3.4167; P = 0.0027). However, we did not discern any HIPEC related overall survival advantages (P = 0.29).
Conclusions
The results from our ovarian cancer study suggest that adjunctive HIPEC proffers a significant progression-free survival advantage and a decreased risk for disease progression. There was, however, no overall survival advantage discerned by the HIPEC group. We also recognize that HIPEC remains controversial, and thus randomized studies evaluating HIPEC compared to standard chemotherapy in the management of ovarian cancer are warranted.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29
Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682–1691
Abaid LN, Micha JP, Rettenmaier MA, Brown JV, Mendivil AA, Lopez KL, Goldstein BH (2013) A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma. Cancer Chemother Pharmacol 72:101–107
Gonzalez Bayon L, Steiner MA, Vasquez Jimenez W, Asencio JM, Alvarez de Sierra P, Atahualpa Arenas F et al (2013) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of advanced epithelial ovarian carcinoma: upfront therapy, at first recurrence, or later? Eur J Surg Oncol 39:109–115
Gourley C, Walker JL, Mackay HJ (2016) Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Am Soc Clin Oncol Educ Book 35:143–151
Los G, van Vugt MJ, Pinedo HM (1994) Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 69:235–241
Tentes AA, Kakolyris S, Kyziridis D (2012) Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy in the treatment of advanced epithelial ovarian cancer. J Oncol 2012:358341
Rettenmaier MA, Mendivil AA, Abaid LN, Brown Iii JV, Wilcox AM, Goldstein BH (2015) Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma. Int J Hyperth 31:8–14
Pomel C, Ferron G, Lorimier G et al (2010) Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol 36:589–593
Eisenhauer EL, Abu-Rustum NR, Sonoda Y et al (2008) The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 108:276–281
Rettenmaier MA, Abaid LN, Erwin MR et al (2009) A retrospective review of the GelPort system in single-port access pelvic surgery. J Minim Invasive Gynecol 16:743–747
Calvert AH, Newell DR, Gunbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756
National Institutes of Health, National Cancer Center Institute (2010) CTCAE: common terminology criteria for adverse events, version 4.03
NCI Clinical Alert (2011) Available online at www.nlm.nih.gov/databases/alerts/ovarian_ip_chemo.html. Accessed 27 April 2011
Wenzel LB, Huang HQ, Armstrong DK et al (2007) Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25:437
Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F et al (2012) Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 22:778–785
McGuire WP, Hoskin WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV EOC. N Engl J Med 334:1–6
Dharmadhikari N, Shah R, Jagannath P (2004) Initial experience with hyperthermic intra peritoneal chemotherapy and cytoreductive surgery. Indian J Cancer 51:189–192
Ryu KS, Kim JH, Ko HS et al (2004) Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol 2004(94):325–332
Sun JH, Ji ZH, Peng KW, Wu HT, Zhang Q, Yonemura Y, Li Y (2016) Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: results of a Chinese retrospective study. Int J Hyperth 32:289–297
Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY et al (2010) Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol 101:149–155
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was supported by the Women’s Cancer Research Foundation.
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This study received institutional review board approval and complied with the ethical standards of the supporting institution and national research committee.
Informed consent
This study was retrospective and accorded a full waiver of authorization under HIPAA by the institutional review board.
Rights and permissions
About this article
Cite this article
Mendivil, A.A., Rettenmaier, M.A., Abaid, L.N. et al. Consolidation hyperthermic intraperitoneal chemotherapy for the treatment of advanced stage ovarian carcinoma: a 3 year experience. Cancer Chemother Pharmacol 80, 405–410 (2017). https://doi.org/10.1007/s00280-017-3376-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-017-3376-8